Antitauon Apr 2026
Using antisense oligonucleotides (ASOs) or "intrabodies" to reduce tau levels within the cell.
Administration of lab-made monoclonal antibodies (mAbs) to target specific tau epitopes. , Semorinemab , Gosuranemab Active Immunotherapy antitauon
Vaccines that stimulate the patient's own immune system to produce anti-tau antibodies. , ACI-35 Intracellular Targeting , ACI-35 Intracellular Targeting Promoting the removal of
Promoting the removal of pathological tau via microglia or through intracellular degradation pathways like the proteasome. Key Therapeutic Strategies Antitauon therapies aim to intervene in this process
In the context of neurodegenerative research, "antitauons" refer to or therapeutic agents designed to neutralize tauons —the prion-like, pathological forms of the tau protein that spread from neuron to neuron. Overview of Tauons and Antitauons
The concept of "tauons" arises from the observation that misfolded tau protein isoforms can propagate through the brain in a characteristic pattern, similar to prions, driving the progression of conditions like Alzheimer's disease. Antitauon therapies aim to intervene in this process through several key mechanisms:
